Biomedicine and New Drugs · us
Another Targeted Treatment Option for ROS1 Lung Cancer: FDA Approves Zidesamtinib for Previously Treated Patients
In a single-arm trial, tumors shrank in 44% of patients previously treated with a ROS1 inhibitor, and nearly 70% of responses lasted at least one year; however, the lack of a control group and mature survival data still limits efficacy comparisons.
For patients with advanced lung cancer harboring ROS1 gene rearrangements, targeted drugs may initially suppress tumors, but resistance, brain progression, or side effects often emerge later. The U.S. Food and Drug Administration (FDA) has approved the next-generation ROS1 inhibitor zidesamtinib, marketed as Jideytro, providing another option after treatment failure.
The approval applies to adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 tyrosine kinase inhibitor. The decision came nearly two months ahead of the originally scheduled review deadline of September 18, 2026; the drug had also previously received FDA Breakthrough Therapy and Orphan Drug designations.
The approval was based on the global Phase 1/2 ARROS-1 trial. All 117 patients included in the efficacy analysis had previously received a ROS1 inhibitor, and the confirmed objective response rate was 44%. Among responders, 82% had responses lasting at least 6 months, and 69% had responses lasting at least 12 months. Responses were assessed by blinded independent central review, and the trial continues to track duration of response, progression-free survival, overall survival, and intracranial efficacy.
Zidesamtinib was designed as a highly selective ROS1 inhibitor, with development goals that include targeting multiple resistance mutations and crossing the blood-brain barrier. These characteristics address key clinical challenges in ROS1-positive lung cancer, as tumors may evolve under treatment pressure and brain metastases frequently become sites of disease progression. However, the drug’s design and the activity signals observed in the trial do not yet directly demonstrate that it is superior to existing therapies.
The overall safety dataset included 446 people who received the drug. Common adverse reactions occurring in at least 15% of patients included edema, peripheral neuropathy, constipation, fatigue, and dyspnea. For patients who may take targeted drugs over the long term, the cumulative burden of side effects, treatment discontinuation rates, and impact on daily life will be important measures beyond response rate.
The evidence supporting this approval comes primarily from an early-stage trial without a control group, so factors such as patient selection cannot be ruled out, and the findings cannot establish how much zidesamtinib may extend survival. Its relative benefit among groups with different prior treatments, resistance mutations, and brain metastases remains to be clarified through more comprehensive stratified data and further follow-up.
Background
Jideytro was originally developed by Nuvalent. GSK secured the approval about one week after completing its $10.6 billion acquisition, making it the company’s first approved lung cancer drug. This quickly transformed the acquisition from a pipeline bet into a commercial asset, but ROS1-positive patients account for only a small proportion of non-small cell lung cancer, and several inhibitors are already on the market. Whether the new drug can ultimately establish a position will depend on its efficacy after resistance, intracranial control, safety, and real-world treatment accessibility.